Related Experiment Video
Updated: Jun 12, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Updates in Childhood Acute Lymphoblastic Leukemia
Sara Zarnegar-Lumley1, Jennifer L McNeer2
1Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Hematology/Oncology Clinics of North America
|June 10, 2026
Summary
Recent studies reveal distinct acute lymphoblastic leukemia (ALL) subgroups driven by specific genomic changes. Targeted therapies and immunotherapies are now being developed for relapsed/refractory pediatric ALL based on these findings.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Molecular studies have identified specific subgroups of acute lymphoblastic leukemia (ALL) driven by genomic aberrations.
- The development of immunotherapy has significantly impacted cancer treatment, with effective agents now available for B-cell ALL (B-ALL).
Purpose of the Study:
- To highlight the progress in understanding molecular drivers of pediatric ALL.
- To discuss the development of targeted agents and immunotherapies for relapsed/refractory pediatric ALL (R/R-ALL).
Main Methods:
- Review of recent molecular studies identifying genomic aberrations in ALL subgroups.
- Analysis of the advent and application of immunotherapy in B-ALL treatment.
- Identification of potential therapeutic targets on leukemic blasts.
Main Results:
- Genomic aberrations, not just chromosomal rearrangements or aneuploidy, define certain ALL subgroups.
- Effective immunotherapeutic agents have been developed for B-ALL.
- Targeted agents and immunotherapies are emerging for pediatric R/R-ALL.
Conclusions:
- Understanding molecular drivers is crucial for advancing pediatric ALL treatment.
- Targeted therapies and immunotherapies represent a promising frontier for R/R-ALL.
